Ann: Recruitment complete in VF00102 Phase 2 clinical trial, page-4

I don't really agree with the leaks part. It was already announced that the screening was closing. I think what we saw was just the beginning of anticipation about the enrolment completion (and locked in timeline for main trial readout). This is an important psychological milestone for a lot of people. The trial data is still blinded so this has nothing to do with results etc. Hopefully the company will now get out there and work on raising the profile again ahead of the trial readout. I think a lot of people are wondering about updated potential valuation for the company (eg has the competitive landscape changed since the inception of the trial). While it costs the company to have analyst reports done to me it may be now worth it as a lot out there simply don't have the means to do it for themselves and so seeing "we value the company at **c per share, with a significant further rerate due in the instance of successful readout.." will give some comfort that that their investment will have a good chance of giving a good return.